HopeStage
Back to all studies
CompletedNCT02566057

Pharmacogenetic Testing to Guide Treatment in Early Psychosis

About this titleRead the official source — NCT02566057
Interventional studyAges 15–64United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 15 years to 64 years.

Listed locations
Glen OaksSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 10, 2014
Recruitment status
Completed
Enrollment listed in the registry
36
Sponsor
Northwell Health
Sponsor type
Unknown or unclear
Study type
Biological
Intervention type
Biological
Locations
United States
Age range
From 15 Years to 64 Years
Official registry ID
NCT02566057
Official title
Show the full official title

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Glen Oaks

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Northwell Health.

Who was this study for?

Listed age limits: 15 years to 64 years.

Want to explore more studies?

Explore studies